TORONTO, ONTARIO--(Marketwired - May 2, 2013) - Biologix Hair Inc. (OTCBB:BLGX) (OTCQB:BLGX) has appointed Edward A.M. Ball, BMBS, BMedSci, DPD, MRCGP, MRCS, to its Medical Advisory Board, on which he will serve with Dr. Arthur G. Handal and Dr. Craig Ziering, Medical Advisory Board Chairman.
Dr. Edward Ball is a hair transplant surgeon and Clinical Director of Ziering UK, a global hair restoration company with ethical practice, clinical excellence and a world-class patient experience at the heart of its ethos. A member of the Royal College of Surgeons of England, Dr. Ball draws on his years of experience in hair restoration, plastic surgery, dermatology, general practice and aesthetic medicine to provide patients with a holistic, first-class service.
Dr. Ball is continually looking to improve upon established techniques and embrace new technology so that his patients consistently receive world-class results. He trained in hair restoration in the United States, having been hand-picked to undertake his Fellowship in Hair Restoration Surgery with Dr. Craig Ziering of Beverly Hills, CA and Dr. Ron Shapiro of Minneapolis, MN. In February 2013, he was the first surgeon to offer robot-assisted follicular unit extraction with the ARTAS System to patients in the United Kingdom at Ziering's London Clinic, having been one of Dr. Ziering's first patients in California to undergo a procedure using the ARTAS System. His ability to empathize with his patients has been greatly enhanced by this experience.
Trained in microsurgery, Dr. Ball is a valued member of the skin cancer surgery team at University Hospital Southampton and an active member of the International Society of Hair Restoration Surgery (ISHRS), the British Society of Hair Restoration Surgery (BSHRS), Royal College of General Practitioners, British Medical Association and the British Association of Cosmetic Doctors and is fully registered with the General Medical Council. Dr. Ball is also a teacher and mentor to novice surgeons new to the field and medical students and has been published in such highly respected medical journals as The British Journal of Plastic Surgery, The British Journal of Dermatology, The Journal of Plastic and Reconstructive Surgery, Burns Journal and Clinical and Experimental Dermatology . He enjoys rowing, surfing, sailing and cycling and previously represented Great Britain in the World Rowing Championships. His wife is also a doctor and the couple has two children.
Ron Holland, Biologix Director and CEO, stated, "Dr. Ball is a welcomed addition to the Biologix Medical Advisory Board. He brings an international clinical perspective to our rapidly expanding network of contracting clinicians and our advisory team."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula - Biologix Revive - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLC, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.
As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.
Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
Disclaimer
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.
